

Contents

List of Contributors XIII

Preface XVII

A Personal Foreword XIX

Part One: Human Transporter Families – Structure, Function, Physiology 1

1 The ABC Transporters: Structural Insights into Drug Transport 3

Robert C. Ford, Alhaji B. Kamis, Ian D. Kerr, and Richard Callaghan

- 1.1 ABC Proteins – Structure and Function 3
 - 1.1.1 ABC Proteins 3
 - 1.1.2 Predicted Topology of ABC Proteins 4
 - 1.1.3 Nucleotide Binding Domains 4
 - 1.1.3.1 Conserved Motifs of NBDs 5
 - 1.1.4 Transmembrane Domains 5
 - 1.1.5 Mechanisms of Transport 5
 - 1.1.6 Energy for Translocation 6
 - 1.1.7 Coupling of ATP Hydrolysis to Transport 7
- 1.2 Structures of ABC Transporters 7
 - 1.2.1 Tertiary Structure 7
 - 1.2.2 Quaternary Structure of ABC Proteins 11
- 1.3 Multidrug Resistance and ABC Transporters 15
 - 1.3.1 P-Glycoprotein 15
 - 1.3.1.1 Historical Background 15
 - 1.3.1.2 The Role of P-gp in Drug Resistance 16
 - 1.3.1.3 Tissue Distribution and Physiological Roles 17
 - 1.3.2 Conformational Changes in the Mechanism of P-gp 17
 - 1.3.3 Comparison of Sav1866 and P-gp Structures 19
 - 1.3.4 Drug Binding Sites in P-Glycoprotein 21
 - 1.3.5 Structural Interpretation of Drug Binding 25
 - 1.3.6 Inhibitors of P-gp 27
 - 1.3.7 What Properties Are Shared by Drugs that Interact with P-Glycoprotein? 29

| | | |
|----------|--|-----------|
| 1.3.8 | Postscript: Further X-ray Crystallographic Studies and a Structure for the Nucleotide-Free State of P-Glycoprotein | 30 |
| 1.4 | Summary | 31 |
| | References | 31 |
| 2 | Biochemistry, Physiology, and Pharmacology of Nucleoside and Nucleobase Transporters | 49 |
| | <i>Marçal Pastor-Anglada, Míriam Molina-Arcas, Pedro Cano-Soldado, and Francisco Javier Casado</i> | |
| 2.1 | Nucleoside and Nucleobase Transporters | 49 |
| 2.1.1 | Equilibrative Nucleoside Transporters | 50 |
| 2.1.2 | Concentrative Nucleoside Transporters | 51 |
| 2.2 | ENT and CNT Tissue Distribution, Regulation, and Physiological Roles | 53 |
| 2.2.1 | ENT Tissue Distribution and Regulation | 54 |
| 2.2.2 | CNT Tissue Distribution and Regulation | 56 |
| 2.2.2.1 | CNTs in Absorptive Epithelia | 57 |
| 2.2.2.2 | CNTs in Liver Parenchymal Cells | 57 |
| 2.2.2.3 | CNTs in Immune System Cells | 58 |
| 2.2.2.4 | CNTs in CNS | 59 |
| 2.2.2.5 | CNTs in Other Specialized Tissues | 60 |
| 2.2.3 | NTs as “Transceptors” | 60 |
| 2.3 | Nucleoside- and Nucleobase-Derived Drug Transport into Cells | 61 |
| 2.3.1 | Transport of Anticancer Drugs | 61 |
| 2.3.2 | Transport of Antiviral Drugs | 63 |
| 2.4 | Drug Transport and Responsiveness to Treatment | 65 |
| 2.4.1 | Analysis of the Role of NTs in Sensitivity to Nucleoside Anticancer Drugs in Cultured Cell Models | 65 |
| 2.4.2 | Studies Linking NT Function to Drug Sensitivity and Clinical Outcome in Cancer Patients | 67 |
| 2.5 | Future Perspectives | 69 |
| | References | 70 |
| 3 | Organic Anion Transporting Polypeptides (Oatps/OATPs) | 81 |
| | <i>Mine Yarim and Meric Koksal</i> | |
| 3.1 | Introduction | 82 |
| 3.2 | Nomenclature and Classification | 82 |
| 3.3 | Tissue Distribution, Structure, and Functions | 83 |
| 3.4 | Substrate Spectrum | 85 |
| 3.5 | Members of the Rodent Oatp Family | 93 |
| 3.5.1 | Oatp1a1 | 93 |
| 3.5.2 | Oatp1a3-v1/v2 | 93 |
| 3.5.3 | Oatp1a4 | 93 |
| 3.5.4 | Oatp1a5 | 94 |
| 3.5.5 | Oatp1a6 | 94 |

| | | |
|--------|---|-----|
| 3.5.6 | Oatp1b2 | 94 |
| 3.5.7 | Oatp1c1 | 95 |
| 3.5.8 | Oatp2a1 | 95 |
| 3.5.9 | Oatp2b1 | 95 |
| 3.5.10 | Oatp3a1 | 95 |
| 3.5.11 | Oatp4a1 | 96 |
| 3.5.12 | Oatp4c1 | 96 |
| 3.5.13 | Oatp6b1/Oatp6c1 | 96 |
| 3.5.14 | PGT-2 | 96 |
| 3.5.15 | TST-1 and TST-2 | 97 |
| 3.6 | Members of Nonmammalian Oatp Family | 97 |
| 3.7 | Members of Human OATP Family | 97 |
| 3.7.1 | OATP1A2 | 97 |
| 3.7.2 | OATP1B1 | 98 |
| 3.7.3 | OATP1B3 | 98 |
| 3.7.4 | OATP1C1 | 99 |
| 3.7.5 | OATP2A1 | 99 |
| 3.7.6 | OATP2B1 | 99 |
| 3.7.7 | OATP3A1 | 100 |
| 3.7.8 | OATP4A1 | 100 |
| 3.7.9 | OATP4C1 | 100 |
| 3.7.10 | OATP5A1 | 100 |
| 3.7.11 | OATP6A1 | 100 |
| 3.8 | Drug Disposition and Drug–Drug Interactions | 101 |
| 3.9 | Computational Approaches | 102 |
| 3.10 | Conclusions | 103 |
| | References | 104 |

4 CNS-Transporters as Drug Targets 113

Klaus Gundertofte

| | | |
|-----|----------------------------------|-----|
| 4.1 | Introduction | 113 |
| 4.2 | Structure of Transporters | 113 |
| 4.3 | Monoamine Transporters | 114 |
| 4.4 | Transporters for Amino Acids | 115 |
| 4.5 | Nonneurotransmitter Transporters | 116 |
| 4.6 | Concluding Remarks | 116 |
| | References | 117 |

Part Two: Drug Transport in Microorganisms and Fungi 119

5 Bacterial Multidrug Transporters: Molecular and Clinical Aspects 121

Olga Lomovskaya, Helen I. Zgurskaya, and Keith Bostian

| | | |
|-------|--|-----|
| 5.1 | Introduction | 121 |
| 5.1.1 | The Multiple Antibiotic Resistance Problem | 121 |

| | | |
|----------|---|------------|
| 5.1.2 | The Superbugs | 121 |
| 5.1.3 | The Multidrug Resistance Transporters | 122 |
| 5.2 | Diversity of Bacterial MDR Efflux Systems | 123 |
| 5.2.1 | ABC Transporters | 124 |
| 5.2.2 | MFS Transporters | 126 |
| 5.2.3 | MATE MDR Transporters | 127 |
| 5.2.4 | SMR MDR Transporters | 128 |
| 5.2.5 | RND MDR Transporters | 129 |
| 5.2.6 | Diversity on a Theme | 133 |
| 5.3 | Accessory Proteins from Gram-Negative Bacteria | 134 |
| 5.4 | Efflux and Antibiotic Resistance | 136 |
| 5.4.1 | Gram-Positive Efflux Resistance | 137 |
| 5.4.2 | Gram-Negative Efflux Resistance | 139 |
| 5.4.3 | Inhibiting Gram-Negative RND Pumps | 141 |
| 5.5 | The Search for Efflux Inhibitors | 143 |
| 5.6 | Challenges and Perspectives | 144 |
| | References | 146 |
| 6 | Membrane Transporters in Pleiotropic Drug Resistance and Stress Response in Yeast and Fungal Pathogens | 159 |
| | <i>Tobias Schwarz Müller, Cornelia Klein, Martin Valachovic, Walter Glaser, and Karl Kuchler</i> | |
| 6.1 | Introduction | 159 |
| 6.2 | ABC Protein Genes in <i>S. cerevisiae</i> | 162 |
| 6.2.1 | The PDR Family | 163 |
| 6.2.2 | The MRP/CFTR Family | 167 |
| 6.3 | Orchestrating Pleiotropic Drug Resistance: The PDR Network | 168 |
| 6.4 | ABC Drug Transporters of Human Fungal Pathogens | 171 |
| 6.5 | Physiological Roles of Drug Transporting ABC Proteins – Search for Substrates | 176 |
| 6.6 | Conclusions and Perspectives | 177 |
| | References | 178 |
| | Part Three: Structure Activity Relationship Studies on ABC Transporter | 195 |
| 7 | QSAR Studies on ABC Transporter – How to Deal with Polyspecificity | 197 |
| | <i>Gerhard F. Ecker</i> | |
| 7.1 | The Problem of Polyspecificity/Promiscuity | 197 |
| 7.2 | QSAR Approaches to Design Inhibitors of P-glycoprotein (ABCB1) | 197 |
| 7.3 | Other ABC Transporter | 206 |
| 7.3.1 | ABCG2 (Breast Cancer Resistance Protein, MXR) | 206 |
| 7.3.2 | ABCC1 and ABCC2 (Multidrug Resistance-Related Proteins 1 and 2) | 207 |

| | | |
|---|---|------------|
| 7.3.3 | ABCB11 (Bile Salt Export Pump) | 208 |
| 7.4 | Novel Methods | 209 |
| 7.5 | Structural Basis for Polyspecificity | 210 |
| 7.6 | Conclusions and Outlook | 210 |
| | References | 211 |
| 8 | Drug Transporter Pharmacophores | 215 |
| | <i>Sean Ekins</i> | |
| 8.1 | Introduction | 215 |
| 8.2 | Database Searching with Transporter Pharmacophores | 217 |
| 8.3 | Summary | 220 |
| | References | 221 |
| | | |
| Part Four: Transporters and ADME 229 | | |
| | | |
| 9 | Biological Membranes and Drug Transport | 231 |
| | <i>Gert Fricker</i> | |
| 9.1 | Biological Membranes | 231 |
| 9.1.1 | Lipid Bilayer | 231 |
| 9.1.2 | Membrane Proteins | 233 |
| 9.1.3 | Membrane Carbohydrates | 233 |
| 9.2 | Membrane Transport | 233 |
| 9.2.1 | Mechanisms of Transport | 233 |
| 9.2.2 | Transport Across Lipid Membranes | 233 |
| 9.2.3 | Protein-Coupled Membrane Transport | 235 |
| 9.2.4 | Kinetics of Carrier-Mediated Transport Processes | 236 |
| 9.2.5 | Ion Gradient-Dependent Transport Processes | 237 |
| 9.2.6 | Cytotic Mechanisms: Transport of Macromolecules | 238 |
| 9.2.7 | Export Proteins | 238 |
| 9.3 | Pharmacokinetic-Relevant Membrane Barriers | 239 |
| 9.3.1 | Intestinal Drug Absorption | 239 |
| 9.3.2 | Liver | 244 |
| 9.3.3 | Kidney | 246 |
| 9.3.4 | Blood–Brain Barrier and Choroid Plexus | 251 |
| | References | 254 |
| | | |
| 10 | Transport at the Blood–Brain Barrier | 263 |
| | <i>Winfried Neuhaus and Christian R. Noe</i> | |
| 10.1 | The Blood–Brain Barrier | 263 |
| 10.2 | Transport Mechanisms Across the Blood–Brain Barrier | 267 |
| 10.3 | The Physical Barrier: Paracellular Transport and Its Characterization | 270 |
| 10.4 | The Efflux Barrier: Transport Proteins at the Blood–Brain Barrier | 272 |
| 10.5 | Transporter of the SLC Transporter Family | 274 |

| | | |
|-----------|---|------------|
| 10.5.1 | Monocarboxylate Transporters | 274 |
| 10.5.2 | Organic Ion Transporters and Transporting Peptides | 276 |
| 10.6 | Transporter of the ABC Transporter Family | 278 |
| 10.6.1 | P-Glycoprotein | 278 |
| 10.6.2 | Multidrug Resistance-Associated Proteins | 282 |
| 10.6.3 | Breast Cancer Resistance Protein | 284 |
| 10.7 | The Metabolic Barrier: Enzymes at the Blood–Brain Barrier | 285 |
| 10.8 | How to Overcome the Blood–Brain Barrier | 286 |
| | References | 286 |
| 11 | Bile Canalicular Transporters | 299 |
| | <i>Dirk R. de Waart and Ronald P.J. Oude Elferink</i> | |
| 11.1 | Introduction | 300 |
| 11.2 | ABCC2 | 301 |
| 11.3 | ABCG2 | 304 |
| 11.4 | ABCB1 | 305 |
| 11.5 | ABCB4 | 306 |
| 11.6 | ABCB11 | 307 |
| 11.7 | ABCG5 and ABCG8 | 308 |
| 11.8 | Canalicular Transporters as Targets for Drug Delivery | 309 |
| | References | 313 |
| 12 | Interplay of Drug Metabolizing Enzymes and ABC Transporter | 325 |
| | <i>Walter Jäger</i> | |
| 12.1 | Combined Role of Cytochrome P450 3A and ABCB1 | 325 |
| 12.2 | Combined Role of Cytochrome P450 3A and OATPs | 329 |
| 12.3 | Combined Role of UDP-Glucuronosyltransferases and ABCC2 | 332 |
| 12.4 | Biopharmaceutical Classification System | 337 |
| | References | 342 |
| 13 | ABC Transporters – From Targets to Antitargets? | 349 |
| | <i>Gerhard F. Ecker and Peter Chiba</i> | |
| 13.1 | Introduction | 349 |
| 13.2 | ABC Transporters as Targets | 349 |
| 13.2.1 | P-Glycoprotein (ABCB1) | 350 |
| 13.2.2 | Other ABC Transporter as Drug Targets | 353 |
| 13.2.2.1 | ABCG2 (Breast Cancer Resistance Protein, MXR) | 353 |
| 13.2.2.2 | ABCC1 and ABCC2 (Multidrug Resistance Proteins 1 and 2) | 353 |
| 13.3 | P-Glycoprotein – An Antitarget? | 354 |
| 13.3.1 | Gastrointestinal Absorption | 354 |
| 13.3.2 | Brain Uptake | 355 |
| 13.4 | Predicting Substrate Properties for P-Glycoprotein | 355 |
| 13.4.1 | Data Sets | 356 |
| 13.4.2 | Classification Models | 356 |
| 13.4.3 | Pharmacophore Models | 358 |

| | | |
|--------|-------------------|-----|
| 13.4.4 | Nonlinear Methods | 358 |
| 13.5 | Conclusions | 358 |
| | References | 359 |

Part Five: A Systems View of Drug Transport 363

14 A Systems Biology View of Drug Transporters 365

Sean Ekins and Dana L. Abramovitz

| | | |
|--------|--|-----|
| 14.1 | Introduction | 365 |
| 14.2 | Regulation of Transporters | 367 |
| 14.3 | Network Analysis of Transporters and Ligands | 368 |
| 14.4 | Transporter Network Examples | 369 |
| 14.4.1 | MetaCore | 369 |
| 14.4.2 | Ingenuity Pathways Analysis | 372 |
| 14.5 | Transporter Gene Expression Data | 376 |
| 14.6 | Summary and Future Perspectives | 377 |
| | References | 379 |

15 Drug Transporters in Health and Disease 387

Barbara Bennani-Baïti and Christian R. Noe

| | | |
|----------|---|-----|
| 15.1 | Introduction | 387 |
| 15.2 | General Mechanisms of Drug Transporter Expression | 388 |
| 15.3 | Neurological Disorders | 389 |
| 15.3.1 | Epilepsy | 390 |
| 15.3.1.1 | Seizure Frequency and RE | 394 |
| 15.3.1.2 | The Role of Drug Transporters in RE Development | 395 |
| 15.3.1.3 | Overcoming RE | 396 |
| 15.3.2 | MDR1 Expression and Neurodegenerative Disorders | 397 |
| 15.4 | Inflammation | 398 |
| 15.4.1 | Inflammation – The Acute-Phase Response | 398 |
| 15.4.2 | BBB and Inflammation | 399 |
| 15.4.3 | Kidney and Inflammation | 400 |
| 15.4.4 | Liver and Inflammation | 401 |
| 15.4.5 | Intestine and Inflammation | 404 |
| | References | 407 |

Index 417

